COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,790 Articles (22,523 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 2860: Articles 28591-28600  | Next

Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells
Stanifer, M. L., Kee, C., Cortese, M., triana, S., Mukenhirn, M., Kraeusslich, H.-G., Alexandrov, T., Bartenschlager, R., Boulant, S.
10.1101/2020.04.24.059667 — Posted: 2020-04-24 Discussion: Offsite
Introductions and early spread of SARS-CoV-2 in France
Gambaro, F., Baidaliuk, A., Behillil, S., Donati, F., Albert, M., Alexandru, A., Vanpeene, M., Bizard, M., Brisebarre, A., Barbet, M., Derrar, F., van der Werf, S., Enouf, V., Simon-Loriere, E.
10.1101/2020.04.24.059576 — Posted: 2020-04-24 Discussion: Offsite
Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a
Blanchard, E. L., Vanover, D., Bawage, S. S., Tiwari, P. M., Rotolo, L., Beyersdorf, J., Peck, H. E., Bruno, N. C., Hincapie, R., Finn, M. G., Michel, F., Lafontaine, E. R., Hogan, R. J., Zurla, C., Santangelo, P. J.
10.1101/2020.04.24.060418 — Posted: 2020-04-24 Discussion: Offsite
Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia
Rodon, J., Noguera-Julian, M., Erkizia, I., Valencia, A., Guallar, V., Carrillo, J., Blanco, J., Segales, J., Clotet, B., Vergara-Alert, J., Izquierdo-Useros, N.
10.1101/2020.04.23.055756 — Posted: 2020-04-24
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
Musarrat, F., Chouljenko, V., Nabi, R., Dahai, A., Jois, S., Kousoulas, K.
10.1101/2020.04.24.060376 — Posted: 2020-04-24 Discussion: Offsite
Comparison of commercial RT-PCR diagnostic kits for COVID-19
van Kasteren, P. B., van der Veer, B., Brink, S. v. d., Wijsman, L., de Jonge, J., van den Brandt, A.-M., Molenkamp, R., Reusken, C. B. E. M., Meijer, A.
10.1101/2020.04.22.056747 — Posted: 2020-04-24
Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations.
Russo, R., Andolfo, I., Lasorsa, V. A., Iolascon, A., Capasso, M.
10.1101/2020.04.23.057190 — Posted: 2020-04-24 Discussion: Onsite
Deep Sentiment Classification and Topic Discovery on Novel Coronavirus or COVID-19 Online Discussions: NLP Using LSTM Recurrent Neural Network Approach
Jelodar, H., Wang, Y., Orji, R.
10.1101/2020.04.22.054973 — Posted: 2020-04-24
Multi-epitope based peptide vaccine design against SARS-CoV-2 using its spike protein
Mitra, D., Shekhar, N., Pandey, J., Jain, A., Swaroop, S.
10.1101/2020.04.23.055467 — Posted: 2020-04-24
SARS-CoV-2 Isolation and Propagation from Turkish COVID-19 patients
Tastan, C., Yurtsever, B., Sir, G., Dilek Kancagi, D., Demir, S., Abanuz, S., Seyis, U., Yildirim, M., Kuzay, R., Elibol, O., Arbak, S., Acikel Elmas, M., Birdogan, S., Sahin, E., Ozcan, O., Sezerman, U., Ovali, E.
10.1101/2020.04.23.056309 — Posted: 2020-04-24 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).